Jane Street Group LLC Takes $46,000 Position in Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP)

Jane Street Group LLC bought a new stake in Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 13,311 shares of the company’s stock, valued at approximately $46,000. Jane Street Group LLC owned approximately 0.82% of Neuphoria Therapeutics Inc. – Common Stock as of its most recent filing with the SEC.

Separately, Lynx1 Capital Management LP acquired a new stake in shares of Neuphoria Therapeutics Inc. – Common Stock in the 4th quarter valued at about $157,000. 15.90% of the stock is currently owned by institutional investors.

Neuphoria Therapeutics Inc. – Common Stock Trading Down 0.7%

Shares of Neuphoria Therapeutics Inc. – Common Stock stock opened at $6.82 on Tuesday. The firm has a 50-day moving average of $5.49. Neuphoria Therapeutics Inc. – Common Stock has a 1 year low of $2.12 and a 1 year high of $12.55.

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) last released its quarterly earnings data on Tuesday, May 20th. The company reported $6.55 earnings per share for the quarter, topping the consensus estimate of ($0.47) by $7.02. The business had revenue of $15.00 million for the quarter. Sell-side analysts forecast that Neuphoria Therapeutics Inc. – Common Stock will post -1.56 earnings per share for the current year.

About Neuphoria Therapeutics Inc. – Common Stock

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.